Vavuranakis Manolis, Boudoulas Konstantinos Dean, Katsarou Ourania, Vrachatis Dimitrios A, Kalogeras Konstantinos I, Papaioannou Theodore G, Siasos Gerasimos, Oikonomou Evangelos, Lazaros George, Vavuranakis Michael-Andreas, Deftereos Spyridon, Tousoulis Dimitrios
13 Astypaleas, Anoixi, Attiki 14569, Greece.
Department of Cardiovascular Medicine, Ohio State University, Columbus, OH, United States.
Curr Pharm Des. 2017;23(9):1328-1333. doi: 10.2174/1381612822666161221143416.
Transcatheter interventions for structural heart disease represent an emerging field in interventional cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior, during and post such interventions. However, currently administered regimens are mainly based in expert consensus recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial septal defect closure, patent foramen oval closure, paravalvular leak closure.
